Orforglipron Shows Positive Efficacy, Tolerability in Weight Management
The oral glucagon-like peptide agonist-1 met its primary end point and all secondary end points in a randomized, double-blind, placebo-controlled…
Primary Care Providers Can Prescribe with Confidence
Information and resources are available to help primary care providers manage OUD with the help of medications for opioid use…
FDA Rationale for Recognition Decision: Voriconazole
FDA Rationale for Recognition Decision: Voriconazole
Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL
Ibrutinib combined with venetoclax significantly improved measurable residual disease and progression-free survival in patients with chronic lymphocytic leukemia.
FDA Rationale for Piperacillin-Tazobactam Breakpoints for Enterobacterales
FDA Rationale for Piperacillin-Tazobactam Breakpoints for Enterobacterales
FDA Rationale for Piperacillin Tazobactam Breakpoints for Pseudomonas aeruginosa
FDA Rationale for Piperacillin Tazobactam Breakpoints for Pseudomonas aeruginosa
FDA Rationale for Recognition Decision: Daptomycin
FDA Rationale for Recognition Decision: Daptomycin
FDA Rationale for Breakpoints Recognition Decision: Polymyxins and Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp.
FDA Rationale for Breakpoints Recognition Decision: Polymyxins and Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp.
Rationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas Maltophilia
Rationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas Maltophilia
FDA Rationale for Recognition Decision: Ceftaroline fosamil
FDA Rationale for Recognition Decision: Ceftaroline fosamil